---
title: "Leqvio (inclisiran) in hypercholesterolemia: Guidelines questions"
description: "Guidelines questions on Leqvio (inclisiran) in hypercholesterolemia, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: What LDL-C targets does the 2026 guideline set (Leqvio site)? When does the 2026 guideline recommend rechecking lipids (Leqvio site)? 2 questions quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/leqvio--hypercholesterolemia/guidelines"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T01:54:55-05:00"
---

# Leqvio (inclisiran) in hypercholesterolemia: Guidelines questions

Manufacturer: Novartis Pharmaceuticals Corporation  
Prescribing information: [Leqvio](https://www.novartis.com/us-en/sites/novartis_us/files/leqvio.pdf)

Questions that apply to every indication of Leqvio are on [Leqvio (inclisiran), all indications](https://www.evicenter.com/medical-information/leqvio).

## Guidelines

<a id="leqvio-guideline-ldl-targets"></a>

### What LDL-C targets does the 2026 guideline set (Leqvio site)?

> “The 2026 Guideline on the Management of Dyslipidemia stresses early and aggressive treatment to get to LDL-C target and that adherence is a key to long-term LDL-C management<sup>1</sup>*”

Source: [LEQVIO: 2026 Guidelines Information | LEQVIO® (inclisiran) | HCP, captured 2026-11-14](https://www.leqviohcp.com/guidelines#:~:text=The%202026%20Guideline%20on%20the,a%20key%20to%20long%2Dterm%20LDL%2DC)

> “LDL-C target of <70 mg/dL for patients with ASCVD not at very high risk<sup>1†</sup>
> LDL-C target of <55 mg/dL for patients at very high risk of ASCVD events<sup>1</sup>”

Source: [LEQVIO: 2026 Guidelines Information | LEQVIO® (inclisiran) | HCP, captured 2026-11-14](https://www.leqviohcp.com/guidelines#:~:text=LDL%2DC%20target%20of%20%3C70%20mg%2FdL,very%20high%20risk%20of%20ASCVD)

> “<sup>†</sup>Very high risk includes a history of multiple major ASCVD events (ACS within past 12 months, history of MI [other than ACS above], history of ischemic stroke, symptomatic PAD) or 1 major ASCVD event and multiple high-risk conditions (age >65 years of age, coronary artery revascularization, current smoker, diabetes, history of heart failure, hypertension, LDL-C >100 mg/dL despite maximally tolerated statin + ezetimibe).<sup>1</sup>”

Source: [LEQVIO: 2026 Guidelines Information | LEQVIO® (inclisiran) | HCP, captured 2026-11-14](https://www.leqviohcp.com/guidelines#:~:text=high%20risk%20includes%20a%20history,mg%2FdL%20despite%20maximally%20tolerated%20statin)

Note: The Leqvio HCP site attributes these statements to the 2026 ACC/AHA multisociety guideline on the management of dyslipidemia (Blumenthal et al., Circulation, 2026). The targets are guideline recommendations for patients with ASCVD.

<a id="leqvio-guideline-follow-up-lipids"></a>

### When does the 2026 guideline recommend rechecking lipids (Leqvio site)?

> “<sup>*</sup>The 2026 Multisociety Guideline recommends that patients receiving lipid lowering therapy (LLT) should receive a follow-up lipid profile 4 to 12 weeks after initiation or intensification, and states that inadequate response to treatment may lead to further intensification of lifestyle or statin regimen changes and/or initiation of a nonstatin LLT. Assessment of adherence to therapy is considered as equally important as response to therapy.”

Source: [LEQVIO: 2026 Guidelines Information | LEQVIO® (inclisiran) | HCP, captured 2026-11-14](https://www.leqviohcp.com/guidelines#:~:text=2026%20Multisociety%20Guideline%20recommends%20that,important%20as%20response%20to%20therapy.)

Note: The guideline statement, as summarized on the Leqvio HCP site, applies to lipid-lowering therapy in general. For Leqvio itself, the Prescribing Information states that the LDL-lowering effect may be measured as early as 30 days after initiation (see the question on checking LDL-C).

## Related pages
- [Medical information: Leqvio (inclisiran): Hypercholesterolemia](https://www.evicenter.com/medical-information/leqvio--hypercholesterolemia)
- [Indication](https://www.evicenter.com/medical-information/leqvio--hypercholesterolemia/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/leqvio--hypercholesterolemia/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/leqvio--hypercholesterolemia/safety)
- [Specific populations](https://www.evicenter.com/medical-information/leqvio--hypercholesterolemia/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/leqvio--hypercholesterolemia/dosing-and-administration)
